Scott McClellan
Search results
mark.mcclellan@duke.edu Focus Areas Value-Based Payment for Care Delivery , Global Health Policy , Value-Based Payment for Medical Products , Real-World Evidence , Biomedical Innovation , Digital Health , U.S. Food and Drug Administration , State Health Care Transformation , Health Care Transformation , COVID-19 Response , Drug-Resistant ...
Director, Duke Margolis Center for Health Policy, Associate of the MA in Bioethics and Science Policy Program. Mark McClellan, MD, PhD, is the Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University.
Mark McClellan, MD, PhD, is director of the Duke-Robert J. Margolis, MD, Center for Health Policy and Senior Fellow and Director of the Health Care Innovation and Value Initiative at the Brookings Institute. A doctor and economist by training, he also has a highly distinguished record in public service and in academic research.
Director of the Duke-Margolis Center for Health Policy at Duke University. Mark McClellan is the Robert J. Margolis Professor of Business, Medicine, and Policy, and founding director of the Duke-Margolis Center for Health Policy at Duke University.
Bio. Mark B. McClellan, MD, PhD, is a doctor and an economist whose work has addressed a wide range of strategies and policy reforms to improve health care, including payment reforms to promote better outcomes and lower costs, methods for development and use of real-world evidence, and approaches for more effective drug and device innovation.
Dr. Mark B. McClellan is the director of the Robert J. Margolis Center for Health Policy and the Margolis Professor of Business, Medicine, and Health Policy at Duke University. He formerly was a senior fellow and director of the Health Care Innovation and Value Initiative at the Brookings Institution, and before that an associate professor with ...
Overview. Mark McClellan, MD, PhD, is a physician-economist who focuses on quality and value in health care, including payment and coverage reform, real-world evidence, more effective policies to support drug and device innovation, and initiatives to increase the impact of health care, public health, and social service programs on population ...
